Industrial - Distribution
Build Your Comparison
Side-by-side financial analysisStock Comparison
TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Diagnostics & Research
Industrial - Machinery
Medical - Diagnostics & Research
Banks - Diversified
TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Industrial - Distribution | Medical - Equipment & Services | Medical - Diagnostics & Research | Industrial - Machinery | Medical - Diagnostics & Research | Banks - Diversified |
| Market Cap | $852M | $4.01B | $127.47B | $11.54B | $174.42B | $896.00B |
| Revenue (TTM) | $333M | $2.81B | $24.78B | $2.35B | $45.20B | $280.33B |
| Net Income (TTM) | $7M | $68M | $3.69B | $254M | $6.86B | $57.05B |
| Gross Margin | 32.6% | 55.1% | 60.7% | 37.7% | 39.4% | 60.0% |
| Operating Margin | 4.1% | 9.0% | 21.0% | 16.9% | 17.8% | 25.9% |
| Forward P/E | 51.9x | 17.2x | 21.3x | 28.7x | 18.9x | 14.4x |
| Total Debt | $129M | $1.71B | $18.42B | $498M | $40.85B | $942.38B |
| Cash & Equiv. | $5M | $1.21B | $4.62B | $364M | $9.86B | $343.34B |
TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Transcat, Inc. (TRNS) | 100 | 352.9 | +252.9% |
| Envista Holdings Co… (NVST) | 100 | 116.6 | +16.6% |
| Danaher Corporation (DHR) | 100 | 114.9 | +14.9% |
| SPX Technologies, I… (SPXC) | 100 | 559.1 | +459.1% |
| Thermo Fisher Scien… (TMO) | 100 | 129.5 | +29.5% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TRNS ranks third and is worth considering specifically for growth.
- 19.2% revenue growth vs DHR's 2.9%
Among these 6 stocks, NVST doesn't own a clear edge in any measured category.
DHR is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
- Beta 0.70, yield 0.7%, current ratio 1.87x
- Beta 0.70 vs NVST's 1.45, lower leverage
SPXC is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 14.2%, EPS growth 17.9%, 3Y rev CAGR 15.7%
- 14.3% 10Y total return vs TRNS's 7.7%
- +44.9% vs DHR's -11.5%
- 7.1% ROA vs NVST's 1.2%, ROIC 13.4% vs 4.8%
TMO doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.
JPM carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- PEG 0.81 vs DHR's 35.21
- Lower P/E (14.4x vs 18.9x), PEG 0.81 vs 8.94
- 20.4% margin vs TRNS's 2.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.2% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (14.4x vs 18.9x), PEG 0.81 vs 8.94 | |
| Quality / Margins | 20.4% margin vs TRNS's 2.0% | |
| Stability / Safety | Beta 0.70 vs NVST's 1.45, lower leverage | |
| Dividends | 1.9% yield, 15-year raise streak, vs DHR's 0.7%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +44.9% vs DHR's -11.5% | |
| Efficiency (ROA) | 7.1% ROA vs NVST's 1.2%, ROIC 13.4% vs 4.8% |
TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 3 of 6 categories
SPXC leads 2 • TRNS leads 0 • NVST leads 0 • DHR leads 0 • TMO leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 842.9x TRNS's $333M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to TRNS's 2.0%. On growth, SPXC holds the edge at +17.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $333M | $2.8B | $24.8B | $2.3B | $45.2B | $280.3B |
| EBITDAEarnings before interest/tax | $40M | $342M | $7.2B | $492M | $10.5B | $81.4B |
| Net IncomeAfter-tax profit | $7M | $68M | $3.7B | $254M | $6.9B | $57.0B |
| Free Cash FlowCash after capex | $20M | $220M | $5.3B | $385M | $6.7B | $100.9B |
| Gross MarginGross profit ÷ Revenue | +32.6% | +55.1% | +60.7% | +37.7% | +39.4% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +9.0% | +21.0% | +16.9% | +17.8% | +25.9% |
| Net MarginNet income ÷ Revenue | +2.0% | +2.4% | +14.9% | +10.8% | +15.2% | +20.4% |
| FCF MarginFCF ÷ Revenue | +5.9% | +7.8% | +21.4% | +16.4% | +14.9% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.8% | +14.4% | +3.7% | +17.4% | +6.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -56.3% | +130.0% | +9.8% | +8.2% | +11.3% | +16.0% |
Valuation Metrics
JPM leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 90% valuation discount to TRNS's 160.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs NVST's 58.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $852M | $4.0B | $127.5B | $11.5B | $174.4B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $976M | $4.5B | $141.3B | $11.7B | $205.4B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | 160.11x | 87.86x | 35.73x | 45.46x | 26.46x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 51.85x | 17.18x | 21.34x | 28.68x | 18.88x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | 58.84x | 35.21x | 2.39x | 12.53x | 0.90x |
| EV / EBITDAEnterprise value multiple | 24.76x | 13.19x | 18.63x | 23.18x | 18.86x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 2.57x | 1.47x | 5.19x | 5.10x | 3.91x | 3.20x |
| Price / BookPrice ÷ Book value/share | 2.83x | 1.34x | 2.44x | 4.99x | 3.31x | 2.47x |
| Price / FCFMarket cap ÷ FCF | 43.60x | 17.40x | 24.23x | 47.86x | 27.72x | 8.88x |
Profitability & Efficiency
SPXC leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $2 for NVST. SPXC carries lower financial leverage with a 0.22x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), NVST scores 7/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.2% | +2.2% | +7.1% | +12.4% | +13.2% | +15.9% |
| ROA (TTM)Return on assets | +1.4% | +1.2% | +4.5% | +7.1% | +6.4% | +1.3% |
| ROICReturn on invested capital | +2.6% | +4.8% | +5.9% | +13.4% | +7.5% | +4.5% |
| ROCEReturn on capital employed | +3.3% | +4.9% | +7.0% | +14.0% | +9.1% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 7 | 5 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.43x | 0.55x | 0.35x | 0.22x | 0.76x | 2.60x |
| Net DebtTotal debt minus cash | $124M | $496M | $13.8B | $134M | $31.0B | $599.0B |
| Cash & Equiv.Liquid assets | $5M | $1.2B | $4.6B | $364M | $9.9B | $343.3B |
| Total DebtShort + long-term debt | $129M | $1.7B | $18.4B | $498M | $40.9B | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.81x | 12.76x | 18.13x | 10.50x | 5.89x | 0.74x |
Total Returns (Dividends Reinvested)
SPXC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SPXC five years ago would be worth $38,893 today (with dividends reinvested), compared to $5,655 for NVST. Over the past 12 months, SPXC leads with a +44.9% total return vs DHR's -11.5%. The 3-year compound annual growth rate (CAGR) favors SPXC at 39.9% vs NVST's -8.3% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +59.7% | +13.4% | -21.7% | +13.2% | -20.7% | -0.5% |
| 1-Year ReturnPast 12 months | +17.9% | +30.4% | -11.5% | +44.9% | +13.4% | +21.8% |
| 3-Year ReturnCumulative with dividends | -1.0% | -22.9% | -13.0% | +173.6% | -9.5% | +138.2% |
| 5-Year ReturnCumulative with dividends | +66.3% | -43.4% | -15.5% | +288.9% | +1.4% | +118.2% |
| 10-Year ReturnCumulative with dividends | +769.1% | -12.0% | +222.6% | +1434.7% | +219.0% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -0.3% | -8.3% | -4.5% | +39.9% | -3.3% | +33.6% |
Risk & Volatility
Evenly matched — TRNS and DHR each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHR is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than NVST's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TRNS currently trades 96.3% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 1.45x | 0.70x | 1.38x | 0.91x | 0.94x |
| 52-Week HighHighest price in past year | $94.76 | $30.42 | $242.80 | $246.68 | $643.99 | $337.25 |
| 52-Week LowLowest price in past year | $50.23 | $18.25 | $160.93 | $152.79 | $385.46 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +80.9% | +74.2% | +93.3% | +72.9% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 54.1 | 52.0 | 61.8 | 50.8 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 155K | 2.8M | 4.2M | 561K | 2.0M | 7.0M |
Analyst Outlook
JPM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: TRNS as "Buy", NVST as "Hold", DHR as "Buy", SPXC as "Buy", TMO as "Buy", JPM as "Buy". Consensus price targets imply 35.4% upside for TRNS (target: $124) vs 5.9% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.86% vs TMO's 0.36%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $123.60 | $28.33 | $231.80 | $252.00 | $599.70 | $339.75 |
| # AnalystsCovering analysts | 10 | 19 | 43 | 12 | 42 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.7% | — | +0.4% | +1.9% |
| Dividend StreakConsecutive years of raises | 0 | — | 9 | 0 | 8 | 15 |
| Dividend / ShareAnnual DPS | — | — | $1.23 | — | $1.69 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +4.2% | +2.4% | 0.0% | +1.7% | +3.9% |
JPM leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). SPXC leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
TRNS vs NVST vs DHR vs SPXC vs TMO vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TRNS or NVST or DHR or SPXC or TMO or JPM a better buy right now?
For growth investors, Transcat, Inc.
(TRNS) is the stronger pick with 19. 2% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Transcat, Inc. (TRNS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TRNS or NVST or DHR or SPXC or TMO or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus Transcat, Inc. at 160. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Danaher Corporation's 35. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — TRNS or NVST or DHR or SPXC or TMO or JPM?
Over the past 5 years, SPX Technologies, Inc.
(SPXC) delivered a total return of +288. 9%, compared to -43. 4% for Envista Holdings Corp (NVST). Over 10 years, the gap is even starker: SPXC returned +1435% versus NVST's -12. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TRNS or NVST or DHR or SPXC or TMO or JPM?
By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.
70β versus Envista Holdings Corp's 1. 45β — meaning NVST is approximately 107% more volatile than DHR relative to the S&P 500. On balance sheet safety, SPX Technologies, Inc. (SPXC) carries a lower debt/equity ratio of 22% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — TRNS or NVST or DHR or SPXC or TMO or JPM?
By revenue growth (latest reported year), Transcat, Inc.
(TRNS) is pulling ahead at 19. 2% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to -63. 7% for Transcat, Inc.. Over a 3-year CAGR, SPXC leads at 15. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TRNS or NVST or DHR or SPXC or TMO or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 1. 6% for Transcat, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 4. 0% for TRNS. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TRNS or NVST or DHR or SPXC or TMO or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Danaher Corporation's 35. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 51. 9x for Transcat, Inc. — 37. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRNS: 35. 4% to $123. 60.
08Which pays a better dividend — TRNS or NVST or DHR or SPXC or TMO or JPM?
In this comparison, JPM (1.
9% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. TRNS, NVST, SPXC do not pay a meaningful dividend and should not be held primarily for income.
09Is TRNS or NVST or DHR or SPXC or TMO or JPM better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
70), 0. 7% yield, +222. 6% 10Y return). Both have compounded well over 10 years (DHR: +222. 6%, NVST: -12. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TRNS and NVST and DHR and SPXC and TMO and JPM?
These companies operate in different sectors (TRNS (Industrials) and NVST (Healthcare) and DHR (Healthcare) and SPXC (Industrials) and TMO (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TRNS is a small-cap high-growth stock; NVST is a small-cap quality compounder stock; DHR is a mid-cap quality compounder stock; SPXC is a mid-cap quality compounder stock; TMO is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. DHR, JPM pay a dividend while TRNS, NVST, SPXC, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.